Covered recipient · General Payments record
JIN SUN L BITAR
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$3,705.55
105 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,655.55 | 104 |
| Consulting Fee | $1,050.00 | 1 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,094.81 | 3 |
| Gilead Sciences, Inc. | $315.84 | 5 |
| AstraZeneca Pharmaceuticals LP | $269.63 | 13 |
| Genentech USA, Inc. | $227.40 | 13 |
| Amgen Inc. | $186.75 | 7 |
| Daiichi Sankyo Inc. | $174.56 | 7 |
| Incyte Corporation | $168.27 | 7 |
| Bayer HealthCare Pharmaceuticals Inc. | $144.58 | 5 |
| Myriad Genetic Laboratories, Inc. | $143.86 | 2 |
| AVEO Pharmaceuticals, Inc. | $95.78 | 4 |
| Pharmacyclics LLC, an AbbVie Company | $71.34 | 3 |
| Blueprint Medicines Corporation | $67.96 | 3 |
| EMD Serono, Inc. | $64.11 | 3 |
| Merck Sharp & Dohme LLC | $61.09 | 3 |
| Janssen Biotech, Inc. | $60.83 | 2 |
| PUMA BIOTECHNOLOGY, INC. | $59.02 | 3 |
| MorphoSys, US Inc. | $57.44 | 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | $54.86 | 2 |
| PFIZER INC. | $50.00 | 2 |
| TOLMAR Pharmaceuticals, Inc. | $48.56 | 2 |
| Myovant Sciences Inc. | $44.66 | 2 |
| EISAI INC. | $42.64 | 2 |
| G1 Therapeutics, Inc. | $40.00 | 2 |
| Sun Pharmaceutical Industries Inc. | $39.50 | 2 |
| Kite Pharma, Inc. | $34.58 | 1 |
| CTI BioPharma Corp. | $23.00 | 1 |
| ABBVIE INC. | $22.86 | 1 |
| GE HealthCare | $21.62 | 1 |
| Seagen Inc. | $20.00 | 1 |
Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JIN SUN L BITAR
NPI 1477940161 · CMS profile ID 5678034
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
LOS ANGELES, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1477940161?year=2022&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JIN SUN L BITAR, NPI 1477940161, CMS profile ID 5678034. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1477940161?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). JIN SUN L BITAR, NPI 1477940161, CMS profile ID 5678034. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1477940161?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- JIN SUN L BITAR, NPI 1477940161, CMS profile ID 5678034, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1477940161?year=2022&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
105 matching records · $3,705.55 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–105 of 105.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corporation | $23.25 | 01/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 958937467 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.00 | 01/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915008737 | CMS |
| EISAI INC. | $23.13 | 01/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908047219 | CMS |
| Genentech USA, Inc. | $23.70 | 01/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950804765 | CMS |
| Incyte Corporation | $22.00 | 01/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 942977351 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $480,931.04 | 36 |
| PY2024 | Principal investigator | $37,600.00 | 11 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
36 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $70,024.43 | 12/31/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous E | No dispute reported | 06/30/2026 | 1232935165 |
| Principal investigator 1 | PFIZER INC. | $57,300.60 | 12/09/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712328 |
| Principal investigator 1 | PFIZER INC. | $7.50 | 12/09/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712526 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $64,980.90 | 12/03/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous E | No dispute reported | 06/30/2026 | 1232935163 |
| Principal investigator 1 | PFIZER INC. | $15.00 | 11/24/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712528 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 11/19/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721923 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 11/19/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722041 |
| Principal investigator 1 | PFIZER INC. | $15.00 | 11/18/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712400 |
| Principal investigator 1 | PFIZER INC. | $7.50 | 11/10/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712330 |
| Principal investigator 1 | PFIZER INC. | $57,300.60 | 11/10/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712460 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 10/17/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721853 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 10/17/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721971 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 10/17/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721973 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 10/17/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722037 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 10/17/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228722039 |
| Principal investigator 1 | Genentech, Inc. | $3,258.31 | 10/14/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | Chemo trastuzumab vs chemo trastuzumab pertuzumab | No dispute reported | 06/30/2026 | 1211542062 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 10/02/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721851 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 10/02/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721855 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 10/02/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228721921 |
| Principal investigator 1 | Genentech, Inc. | $1,062.50 | 10/01/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | Chemo trastuzumab vs chemo trastuzumab pertuzumab | No dispute reported | 06/30/2026 | 1211542058 |
| Principal investigator 1 | PFIZER INC. | $13,123.52 | 09/16/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228759085 |
| Principal investigator 1 | Genentech, Inc. | $562.50 | 09/03/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | Chemo trastuzumab vs chemo trastuzumab pertuzumab | No dispute reported | 06/30/2026 | 1211542054 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $88,410.24 | 08/31/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous E | No dispute reported | 06/30/2026 | 1232935389 |
| Principal investigator 1 | PFIZER INC. | $4,850.00 | 08/08/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228766947 |
| Principal investigator 1 | AstraZeneca UK Limited | $10,292.00 | 08/01/2025 | Covered Recipient Teaching Hospital Cedars-sinai Medical Center | ROSY-O Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment | No dispute reported | 06/30/2026 | 1185539525 |
| Principal investigator 1 | PFIZER INC. | $45,792.00 | 06/26/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228777164 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228786825 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228787165 |
| Principal investigator 1 | PFIZER INC. | $600.00 | 06/23/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228789055 |
| Principal investigator 1 | PFIZER INC. | $7,437.00 | 05/06/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228782078 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/29/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228786598 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/29/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228786690 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/29/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228789237 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/12/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228788431 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 01/30/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228787161 |
| Principal investigator 1 | AstraZeneca UK Limited | $47,391.44 | 01/28/2025 | Covered Recipient Teaching Hospital Cedars-sinai Medical Center | CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease | No dispute reported | 06/30/2026 | 1185539523 |